Rinvoq ER 45 MG tablet UU 28S
Ended Awarded
- Contract number
- SPE2DX25FVHEL
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $274,266
Award facts
- Contract value 100% obligated
- $274,266.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
AmerisourceBergen Drug Corp was awarded a delivery order valued at $274,266.46 by the Defense Logistics Agency's Medical Supply Chain to supply RINVOQ ER 45 mg tablets in a quantity of 28 units. The contract was awarded on July 22, 2025, with an ultimate completion date of July 23, 2025, utilizing firm fixed-price pricing with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling value through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs.
As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp demonstrates significant capacity to meet federal medical procurement requirements through open competition. The company maintains an extensive portfolio of pharmaceutical products and medical supplies serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. RINVOQ ER (upadacitinib extended-release), a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other autoimmune conditions, represents the type of specialized pharmaceutical commodity routinely supplied through the company's DLA contracts. The competitive award reflects AmerisourceBergen's continued role as a critical vendor for military medical supply chain operations.
Quick answers
Who was awarded contract SPE2DX25FVHEL?
SPE2DX25FVHEL was awarded to Amerisourcebergen Drug Corp by Medical Supply Chain (Troop Support) on July 22, 2025.
How much is contract SPE2DX25FVHEL worth?
The government has obligated $274,266 on SPE2DX25FVHEL.
Is contract SPE2DX25FVHEL an order under another contract?
Yes. SPE2DX25FVHEL is a delivery order under SPE2DX15D1022, an indefinite delivery contract.
Was contract SPE2DX25FVHEL competed?
The extent of competition for SPE2DX25FVHEL was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award